23,093 Shares in Qiagen N.V. $QGEN Purchased by SG Americas Securities LLC

SG Americas Securities LLC acquired a new stake in Qiagen N.V. (NYSE:QGEN) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 23,093 shares of the company’s stock, valued at approximately $1,032,000.

Other large investors have also made changes to their positions in the company. MAI Capital Management increased its holdings in Qiagen by 998.9% in the 2nd quarter. MAI Capital Management now owns 978 shares of the company’s stock worth $47,000 after acquiring an additional 889 shares in the last quarter. Farther Finance Advisors LLC increased its stake in shares of Qiagen by 400.5% during the second quarter. Farther Finance Advisors LLC now owns 1,061 shares of the company’s stock worth $51,000 after purchasing an additional 849 shares in the last quarter. Allworth Financial LP raised its position in shares of Qiagen by 260.1% during the 2nd quarter. Allworth Financial LP now owns 1,102 shares of the company’s stock worth $53,000 after purchasing an additional 796 shares during the last quarter. GAMMA Investing LLC lifted its stake in Qiagen by 375.5% in the 3rd quarter. GAMMA Investing LLC now owns 1,241 shares of the company’s stock valued at $55,000 after buying an additional 980 shares in the last quarter. Finally, Cullen Frost Bankers Inc. lifted its stake in Qiagen by 13,144.4% in the 2nd quarter. Cullen Frost Bankers Inc. now owns 1,192 shares of the company’s stock valued at $57,000 after buying an additional 1,183 shares in the last quarter. 70.00% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on the company. Citigroup cut Qiagen from a “buy” rating to a “neutral” rating and reduced their target price for the company from $57.89 to $52.63 in a report on Thursday, December 11th. Barclays reissued an “overweight” rating and issued a $57.89 price target (up from $55.79) on shares of Qiagen in a research note on Monday, December 15th. Weiss Ratings restated a “hold (c)” rating on shares of Qiagen in a report on Monday, December 29th. Finally, Wall Street Zen cut Qiagen from a “buy” rating to a “hold” rating in a report on Saturday, January 10th. Two research analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the company’s stock. According to MarketBeat, Qiagen has a consensus rating of “Hold” and an average target price of $52.84.

Qiagen Trading Down 1.5%

NYSE QGEN opened at $47.64 on Monday. The company has a debt-to-equity ratio of 0.45, a quick ratio of 2.30 and a current ratio of 2.60. The firm has a market cap of $10.06 billion, a price-to-earnings ratio of 24.60, a PEG ratio of 2.19 and a beta of 0.66. The firm has a 50 day simple moving average of $48.17 and a 200-day simple moving average of $49.40. Qiagen N.V. has a one year low of $39.61 and a one year high of $54.61.

Qiagen (NYSE:QGEN) last released its earnings results on Thursday, November 6th. The company reported $0.64 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.61 by $0.03. Qiagen had a net margin of 19.58% and a return on equity of 14.80%. The company had revenue of $532.58 million for the quarter, compared to analyst estimates of $525.68 million. During the same period in the prior year, the business earned $0.60 EPS. The firm’s quarterly revenue was up 6.2% on a year-over-year basis. Equities research analysts anticipate that Qiagen N.V. will post 2.26 EPS for the current fiscal year.

Qiagen Company Profile

Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions.